Using MRI to predict the fate of excitotoxic lesions in rats - Laboratoire de Neurosciences Cognitives Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2018

Using MRI to predict the fate of excitotoxic lesions in rats

Résumé

Excitotoxic lesions are frequently used to assess the role of cerebral structures in cognitive processes in rodents. However, the precise site and extent of these lesions remain unknown without histological verifications. Using a 7-Teslas MRI system and a T2-weighted turbo-RARE sequence, MR images were acquired at several time points following NMDA lesions (1h, 6h, 24h, 48h, 1 week and 2 weeks). NMDA infusions into the parenchyma induced a clear and delineable hyperintense signal from 1h up to 1-week post-surgery. Hyperintensity volumes were compared with NeuN and Cresyl violet histological quantifications of the lesion magnitude. NMDA-induced hypersignal is observed as soon as 1h post-injection and is a reliable estimate of the presence (or absence) of a lesion. Compared to NeuN, Cresyl violet staining underestimates the extent of the lesion in significant proportions. The MRI hyperintensity generated by NMDA instillation into the parenchyma can be used as a powerful tool to confirm the diffusion of the drug into the cerebral tissue, to ascertain the locus of injection and predict with a high success rate the fate of NMDA lesions as soon as 1h post-surgery. This approach could be very useful in a large variety of lesion studies in rodents.
Fichier principal
Vignette du fichier
Cholvin et al 2018 PLOS one.pdf (9.63 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-01841718 , version 1 (17-07-2018)

Identifiants

  • HAL Id : hal-01841718 , version 1

Citer

Thibault Cholvin, Lisa Giorgi, Nathalie Baril, Jean-Michel Brezun, Bruno Poucet, et al.. Using MRI to predict the fate of excitotoxic lesions in rats. PLoS ONE, 2018. ⟨hal-01841718⟩
75 Consultations
53 Téléchargements

Partager

Gmail Facebook X LinkedIn More